Evidence map›Paper›PMID 38153524›Full record

SynthesisInflammation research : official journal of the European Histamine Research Society ... [et al.]2024

Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.

Husam Abu Suilik, Fouad Jaber, Mohamed Abuelazm, Alaa Ramadan, Mohamed A Elzeftawy, Amr Elrosasy, Rana Ahmed Youssef, Basel Abdelazeem, Jana G Hashash, Francis A Farraye and 1 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 4 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Raising the bar in ulcerative colitis management.Therapeutic advances in gastroenterology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Husam Abu Suilik *Faculty of Medicine, Hashemite University, Zarqa, Jordan.
Fouad Jaber *Department of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, USA. Fouad.jaber.md@gmail.com.
Mohamed AbuelazmFaculty of Medicine, Tanta University, Tanta, Egypt.
Alaa RamadanFaculty of Medicine, South Valley University, Qena, Egypt.
Mohamed A ElzeftawyFaculty of Medicine, Tanta University, Tanta, Egypt.
Amr ElrosasyFaculty of Medicine, Cairo University, Cairo, Egypt.
Rana Ahmed YoussefFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Basel AbdelazeemWest Virginia University, Morgantown, WV, USA.
Jana G HashashDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Francis A FarrayeDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Hassan GhozDivision of Gastroenterology and Hepatology, University of Missouri-Kansas City, Kansas City, MO, USA.
Mayo Clinic in Florida · USTanta University · EGUniversity of Missouri–Kansas City · USAlexandria University · EGCairo University · EGHashemite University · JOMichigan State University · USSouth Valley University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveOne sphingosine-1-phosphate (S1P) receptor modulator is approved (ozanimod) and another (etrasimod) is under investigation for the induction and maintenance of remission of ulcerative colitis (UC). We aim to evaluate the efficacy and safety of S1P modulators in patients with active UC.

methodsWe conducted a systematic review and meta-analysis synthesizing randomized controlled trials (RCTs), which were retrieved by systematically searching: PubMed, Web of Science, SCOPUS, and Cochrane through May 13th, 2023. We used the fixed-effect model to pool dichotomous data using risk ratio (RR) with a 95% confidence interval (CI).

resultsFive RCTs with a total of 1990 patients were included. S1P receptor modulators were significantly associated with increased clinical response during both the induction (RR 1.71 with 95% CI [1.50, 1.94], P = 0.00001) and maintenance phases (RR 1.89 with 95% CI [1.33, 2.69], P = 0.0004); clinical remission rates during both induction (RR 2.76 with 95% CI [1.88, 4.05], P = 0.00001) and maintenance phases (RR 3.34 with 95% CI [1.41, 7.94], P = 0.006); endoscopic improvement during both induction (RR 2.15 with 95% CI [1.71, 2.70], P = 0.00001) and maintenance phases (RR 2.41 with 95% CI [1.15, 5.05], P = 0.02); and histologic remission during both induction (RR 2.60 with 95% CI [1.89, 3.57] [1.17, 2.10], P = 0.00001) and maintenance phases (RR 2.52 with 95% CI [1.89, 3.37], P = 0.00001). Finally, there was no difference regarding safety outcomes as compared to placebo in both the induction and maintenance phases.

conclusionS1P receptor modulators are effective in inducing and maintaining remission in patients with moderate to severe UC.

Indexed as

Colitis, UlcerativeLysophospholipidsSphingosine 1 Phosphate Receptor ModulatorsHumansRandomized Controlled Trials as TopicSphingosineSphingosine-1-Phosphate ReceptorsLysophospholipidsSphingosinesphingosine 1-phosphateSphingosine 1 Phosphate Receptor ModulatorsSphingosine-1-Phosphate ReceptorsClinical trialColitisColonImmune systemInflammation

Identifiers

PMID38153524
OpenAlexW4390346403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.